possess potent inhibitory activity in a cell-based assay measuring inhibition of oncostatin M signalling in a reporter cell line utilising a secreted placental alkaline phosphatase (SPAP) readout. In this paper we report the isolation and structure elucidation of the compoundsand describe some of their biological properties.
Ansmycins are described as antibiotics containing an aliphatic ansa bridge connecting two nonadjacent positions of an aromatic nucleus, and comprise a broad family of microbial secondary metabolites including the rifamycins, streptovaracins, tolypomycins and geldanamycins, which possess numerous diverse biological activitiesl\ Geldanamycin,a benzoquinoneansamycin, was discovered in 1970 by De Boer et al2) possessing activity in vitro against bacteria, protozoa, fungi and mammalian tumour cells. Geldanamycin and related compounds have since been the subject of intensive investigation as potential antitumour agents3~5); geldanamycin itself appears to exert its anti-tumour activity principally through binding to the TV-terminal ATP/ADP binding domain of heat shock protein 90 (Hsp90), a molecular chaperone, causing inhibition of its inherent ATPase activity, which ultimately results in disruption of the cell cycle6). Oncostatin M(OSM), a member of the IL-6 cytokine family, is a pleiotropic cytokine with pro-inflammatory activity. OSMupregulates adhesion molecule expression in endothelial cells7) synergises with IL-1 to promote cartilage degradation8) whilst administration of anti-OSM antibodies ameliorates both collagen-and pristane-induced arthritis in mice9). Furthermore, OSMis released from ex-vivo cultures of inflamed synovial tissue10) and is present both in the pp. 657 -663 synovium8^and syovial fluid of patients with rheumatoid arthritis8). Inhibition of OSMtherefore represents a novel therapeutic opportunity for the treatment of rheumatoid arthritis. In the course of screening in a cellular assay for inhibitors of OSM signalling we have isolated and characterised novel non-benzoquinone ansamycins related to geldanamycin, together with the known compound reblastatin (see Figure 1) 
CaCO3
(1), pH 7) which was incubated at 28QC for 6 days using an orbital shaker. A1%inoculum was transferred to production medium (in g/liter: soya flour (Arkasoy; 10), glucose (50), peptone (4), Lab Lemco (Oxoid Ltd; 4), yeast extract (1), NaCl (2.5), CaCO3 (1), pH.7.6; 4X250ml in 1liter Erlenmeyer flasks) and incubated for 8 days at 28°C using an orbital shaker.
Prefractionation of S6699 Fermentation
Whole fermentation broth was mixed with an equal volume of methanol. After standing for 1 hour at room temperature, cells were removed by centrifugation (2500rpmX30minutes).
The supernatant was taken, methanol was removed by rotary evaporation, and the volume of aqueous concentrate was adjusted to -800ml (0. 1% aqueous phosphoric acid). This was pumped through a column containing copolymer resin (Amberchrom CG161, Rohm and Haas), the resin was washed with 0.1% aqueous phosphoric acid and adsorbed components were eluted with methanol (1 liter Cell cultures were set up as described above, with the exception that in place of cytokine, 14C-leucine was added (0.2/iCi/well; Amersham). Cells were harvested using Skatron cell harvester following 18 hours incubation, and incorporated 14C-leucine measured using a scintillation c ounter.
PPD Proliferation Assay
Blood from healthy volunteers was diluted 1 : 3 with phosphate buffered saline (PBS), layered onto Lymphoprep (NycomedUK) and centrifuged at 600Xg for 30 minutes at 
Results and Discussion
The structure of 3 was identified by using 2D Correlation NMR experiments (HMQC, HMBC, Gradient assisted PSDQFCOSY). NMR data was in accordance with that previously reported for ,reblastatin12), an inhibitor of Rb phosphorylation.
Compound 2 gave data similar to 3, but with the absence of OCH3 at 3.67/59.4ppm
(!H/13C respectively) and the presence of a new signal (17-OH) at 7.66ppm in the !H spectrum which gave no HMQC correlation. For 1, 2D-NMR data experiments were employed. 1 gave data similar to both 2 and 3, however differences in the chemical shifts about the aromatic ring combined with the loss of OCH3or OHsignal and the appearance of an HMQC correlation for CH-17 gave rise to the reported structure. An HMBC correlation from H-15 to C-17 supported this conclusion. MSanalysis showed that 1 gave a protonated molecular ion at m/z 519 (M+H+)and a deprotonated molecular ion at m/z 5 17 (M-H~) indicating that the molecular weight was 518. Similarly, 2 gave a protonated molecular ion at m/z 535 (M+H+) and a deprotonated molecular ion at m/z 533 (M-H~) indicating its molecular weight was 534, whilst 3 gave a protonated molecular ion at m/z 549 (M+H+) and a deprotonated molecular ion at m/z 547 (M-H~) indicating that its molecular weight was 548. Accurate mass values were also consistent with the molecular formulae proposed. The IC50 values of compounds 1, 2 and 3 in the OSMSPAP assay were 0.7 /iM, 4.9 /iM and 0. 16 /iM respectively. However, the compounddid inhibit protein synthesis in A549cells in a concentration dependent manner ( Figure  3 .2). 1 inhibited protein synthesis by approx. 46% at a concentration of 1 jig/ml. In this cell line, this degree of protein synthesis inhibition was not accompanied by an inhibition of either SPAP production or cell viability. This implies that in A549 cells, SPAP production is largely unaffected by partial block of protein synthesis caused by 1.
In a further experiment, 1 produced near maximal In conclusion therefore, we have shownthat compound1 inhibits OSMand IL6-driven SPAP production in HepG2B6 cells whilst having no effect on TNFa-driven SPAP production in A549 cells. The mechanism by which compound 1 causes inhibition of SPAP production in HepG2B6cells remains unclear, and does not appear to be associated with inhibition of either protein synthesis or cell viability. However, the protein synthesis inhibitory activity of the compound in A549 cells coupled to its ability to inhibit lymphocyte proliferation suggest that its biological activities are somewhat non-specific, and not necessarily attributable to inhibition of either OSMor IL6 signalling.
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